Abstract: The present invention generally concerns new non-agglomerating bioconjugates of amylin-mimetic compounds with polyethylene glycol, and their use mainly in the treatment of diseases associated with extracellular amyloid deposition or accumulation that contributes to the dysfunction or failure of systemic organs such as the pancreas.

Abstract: The present disclosure concerns new non-agglomerating bioconjugates of amylin, amylin-mimetic compounds, and combinations comprising the same. Methodology of making and using are provided herein. In some embodiments, an instant non-agglomerating amylin bioconjugate can be used for treating a disease associated with a lack of natural production of amylin and/or deposition or accumulation of extracellular amyloid fibers, which contribute to the dysfunction or failure of systemic organs such as the pancreas or the brain.